Related Experiment Video
Updated: Mar 10, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy
Rebecca Lee1, Shyam Kottilil1, Eleanor Wilson2
1Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Abstract:
Treatment for chronic hepatitis C virus (HCV) has evolved rapidly from an interferon based regimen of modest efficacy with significant adverse events to a well-tolerated, highly effective all-oral directly acting antiviral (DAA) therapy. Although significant improvement in sustained virologic responses (SVR) has been reported with new DAAs for genotypes 1 and 4, effective treatments for genotype 3 have been lacking, and a single pill that can yield high SVR rates against HCV genotypes 1-6 has not been available until now. Sofosbuvir (a pangenotypic NS5B inhibitor) and velpatasvir (a pangenotypic NS5A inhibitor) were recently approved in a fixed-dose combination pill. The availability of this pangenotypic pill holds promise for providing highly effective treatment with minimal laboratory testing for chronic HCV worldwide.
More Related Videos
09:29Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Retrovirus Life Cycles
Pharmacogenomics: Identification of New Drug Targets
Pharmacokinetics: Drug–Food and Drug–Viral Interactions